Modulation of imidazoline I 2 binding sites by CR 4056 relieves postoperative hyperalgesia in male and female rats

Autor:	Gianfranco Caselli, Ilaria Menghetti, Dario Tremolada, Marco Lanza, Flora Ferrari
Rok vydání:	2014
Předmět:	Male sex differences Narcotic Antagonists Analgesic (+)-Naloxone Pharmacology Rats Sprague-Dawley chemistry.chemical_compound CR4056 Idazoxan Threshold of pain Animals Medicine Benzofurans drug synergism Analgesics Pain Postoperative Binding Sites Morphine Naloxone business.industry Imidazoles Antagonist Yohimbine Adrenergic alpha-2 Receptor Antagonists Efaroxan Research Papers Analgesics Opioid chemistry Hyperalgesia imidazoline-2 receptors Quinazolines Female Imidazoline Receptors medicine.symptom postoperative pain business medicine.drug
Zdroj:	British Journal of Pharmacology
ISSN:	1476-5381 0007-1188
Popis:	Background and Purpose CR4056 is a novel imidazoline-2 (I2) ligand exhibiting potent analgesic activity in animal models of pain. In this study, we investigated the effects of CR4056 in a well-established model of postoperative pain where rats develop hyperalgesia in the injured hind paw. Experimental Approach By measuring paw withdrawal threshold to mechanical pressure, we studied the pharmacology of CR4056, potential sex differences in pain perception and response to treatment, and the pharmacodynamic interaction of CR4056 with morphine. Key Results Oral CR4056 and subcutaneous morphine dose-dependently reversed the hyperalgesic response. Analgesic effects of CR4056 were completely suppressed by the non-selective imidazoline I2/α2-adrenoceptor antagonist idazoxan, were partially reduced (∼30%; P < 0.05) by the selective α2-adrenoceptor antagonist yohimbine, but were not influenced by the non-selective I1/α2-adrenoceptor antagonist efaroxan or by the μ opioid receptor antagonist naloxone. We found no differences in responses to CR4056 or morphine between male and female rats. However, females had a lower pain threshold than males, and needed lower doses of drugs to reach a significant analgesia. When CR4056 and morphine were combined, their median effective doses were lower than expected for additive effects, both in males and in females. Isobolographic analysis confirmed a synergism between CR4056 and morphine. Conclusions and Implications CR4056 is a novel pharmacological agent under development for postoperative pain both as stand-alone treatment and in association with morphine. CR4056 has successfully completed Phase I studies for tolerability and pharmacokinetics in healthy volunteers, and is currently entering the first proof-of-concept study in patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aef211cad36c24534c3ae160bbd67424 https://doi.org/10.1111/bph.12728 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.